Mild Cognitive Impairment in Relation to Alzheimer’s Disease: An Investigation of Principles, Classifications, Ethics, and Problems

Abstract

Mild Cognitive Impairment (MCI) is a diagnostic category indicating cognitive impairment which does not meet diagnostic criteria for dementia such as Alzheimer’s disease. There are public health concerns about Alzheimer’s disease (AD) prompting intervention strategies to respond to predictions about the impacts of ageing populations and cognitive decline. This relationship between MCI and AD rests on three interrelated principles, namely, that a relationship exists between AD and MCI, that MCI progresses to AD, and that there is a reliable system of classification of MCI. However, there are also several ethical issues and problems arising in the AD/MCI relationship. These include early diagnosis and interventions, the effects on people with MCI, and the newer neuroimaging and neuropharmacological approaches used in diagnosis and treatment. All these issues pose questions about the principles of MCI in relation to AD, with implications for how MCI is understood, diagnosed, treated, and experienced by patients. This article analyses four challenging areas for neuroethics: the definition and diagnosis of MCI; MCI in relation to AD; clinical implications of MCI for ethical disclosure, diagnosis, and treatment; and the research implications of MCI. The significant connections between these areas are often overlooked, together with uncertainties overall. Patients, healthcare systems and society are best served by informed clinicians, academics and researchers. After 35 years, the store of MCI knowledge is expanding and evolving.

Exploring the Influence of Gut–Brain Axis Modulation on Cognitive Health: A Comprehensive Review of Prebiotics, Probiotics, and Symbiotics

“…In the case of MCI, cognitive, attentional, and memory functions are no longer as proficient as in healthy aging, but the decline has not yet reached the level of dementia. MCI can be considered a precursor to dementia, where solving complex tasks and understanding written information become challenging [ 83 ]. The prevalence of MCI is 6.7% at the age of 60–64 years, 8.4% at 65–69 years, 10.1% at 70–74 years, 14.8% at 75–79 years, and 25.2% at 80–84 years.…”

New Community and Sociohealth Challenges Arising from the Early Diagnosis of Mild Cognitive Impairment (MCI)

“…With the development and application in clinical practice of more accessible and accurate diagnostic biomarkers (plasma biomarkers) [ 40 ], it is expected that the number of cases of AD diagnosed in prodromal or MCI stages will increase exponentially in the coming years. Unfortunately, the early diagnosis of progressive neurodegenerative disorder raises a number of ethical concerns, such as social stigma, psychosocial damage, driving fitness, available social care services, and lack of adaptation to the new scenario [ 41 ]. Therefore, involvement and counseling of the patients and their relatives before and after a syndromic and etiological diagnosis has been established as essential [ 1 ].…”

Deep Ensemble learning and quantum machine learning approach for Alzheimer’s disease detection

“…Alzheimer's disease (AD) is a degenerative brain disorder that diminishes memory and other critical mental abilities 1 . More broadly, dementia is described as the greatest global challenge for health care and social services, where globally approximately 50 million people were living with dementia in 2022 2 .…”